Company presentations entries 2026

Arphamid develops therapeutics that keep cancer patients on life-saving treatment. We target debilitating complications that force patients to reduce or stop chemotherapy. Dimiracetam, a glutamate modulator (Phase 2-ready), prevents early symptoms of oxaliplatin neuropathy. RF4662 reduces breakthrough pain episodes via GPR103 antagonism (IND-ready). RF4442 addresses cachexia via GPR10 antagonism. We seek €25M to advance three value-inflection milestones toward a €3.5B market.

Tuesday, May 5, 13:45 - 15:00, room Singapore

Most cell and stem cell therapies fail beyond blood cancers because delivery cannot preserve function or safety in solid tissue. ClexBio solves this with a universal platform for solid tissue and organ replacement that mimics biology, prevents immune rejection, and enables durable persistence. This unlocks regenerative therapies for liver failure, type 1 diabetes, and heart disease. Backed by top investors, we are raising $10M toward IND studies and pharma partnerships.

Concept Life Sciences is a leading contract research organisation (CRO) serving the global life sciences industry. For over 25 years, the company, and its heritage companies, have provided consultative and collaborative drug discovery and development services. Our approach, supported by passionate scientists and world-leading capabilities, enables clients to overcome complex scientific challenges across a broad range of therapeutic areas, improving program success rates.

Cube Biotech specializes in solving complex problems in protein research, with a specific emphasis on the challenging class of membrane proteins. We take pride in covering all stages of protein preparation utilizing our NativeMP copolymer stabilization platform, protein purification capabilities, biophysical target characterization applications, and structure determination via cryo-EM or crystallography.

Effective topical treatment of the esophagus is difficult due to the ultra-short transit time of only seconds from mouth to stomach. EsoCap has developed a versatile drug delivery platform that enables efficient, localized administration of small molecules, antibodies, and RNA-based therapies. The technology supports improved treatment of EoE, reflux disease, esophageal cancer, and other gastrointestinal disorders by enhancing mucosal contact and therapeutic precision.

HDI Global offers a wide range of insurance solutions for startups, medium-sized businesses, large companies, and international corporate groups. As a partner in transformation, HDI combines local expertise with a global network, providing worldwide coverage and innovative solutions for new technologies and risks. For life sciences, HDI offers specialised cover - such as product liability, recall costs, R&D protection, clinical trials, logistics, and cyber insurance.

KBI Biopharma is a leading CDMO providing integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. We work closely to personalize and accelerate drug development programs. With world-class analytics and scientific expertise, we deliver robust process development and clinical and commercial cGMP manufacturing services for mammalian and microbial programs. We help clients advance drug candidates into the clinic.

Oculis is a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet needs. Oculis’ late-stage pipeline includes OCS-01, a topical eye drop for DME; Privosegtor, a neuroprotective candidate for optic neuritis and NAION; and Licaminlimab, a topical anti-TNFα for DED. Headquartered in Switzerland, Oculis is led by an experienced management team and is supported by leading healthcare investors.

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on developing and commercializing innovative medicines for rare neuromuscular diseases with high unmet medical need. Santhera holds an exclusive worldwide license from ReveraGen to AGAMREE® (vamorolone), a dissociative steroid investigated in DMD as an alternative to corticosteroids. AGAMREE is approved for DMD in the U.S., EU, UK, China, Hong Kong, and Canada.

Ultimate Medicine (UM) is a Swiss preclinical biotech focused on maximizing the healthspan of patients with Alzheimer's disease and other dementias. The company is pioneering a class of small molecules targeting elevated levels of a novel toxic metabolite that disrupts critical neuronal functions and accelerates disease progression. The company’s lead program is an oral small-molecule inhibitor designed to block metabolite synthesis.

Monday, May 4, 16:00 - 16:15, room Singapore